Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference
11 mai 2022 16h02 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 11, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that...
Nurix Therapeutics to Host R&D Day on May 26, 2022
09 mai 2022 16h02 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced it...
Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting
08 avr. 2022 13h02 HE
|
Nurix Therapeutics, Inc.
Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide drug (IMiD) activity of NX-2127, resulting in robust tumor cell killing Animal...
Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update
07 avr. 2022 16h01 HE
|
Nurix Therapeutics, Inc.
Dosed first patient in the Phase 1 trial of DeTIL-0255, Nurix’s drug-enhanced tumor infiltrating lymphocyte (TIL) program Awarded Innovation Passport for Entry into Innovative Licensing and Access...
Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors
05 avr. 2022 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 05, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced...
Nurix Therapeutics Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
04 avr. 2022 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs,...
Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607
29 mars 2022 16h01 HE
|
Nurix Therapeutics, Inc.
NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types The ILAP aims to accelerate the time to market for innovative medicines that address the...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
09 mars 2022 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, March 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....
Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting
08 mars 2022 16h47 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical...
Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....